Applied Materials, a major semiconductor equipment producer, plans to expand its Blackburn Industrial Park facility in Gloucester by constructing new manufacturing and logistics buildings. This expansion will involve decommissioning two existing wind turbines and is aimed at increasing efficiency and meeting the growing demand for computer chips. The company also anticipates an increase in its local workforce and is designing its new buildings to be "solar ready."

Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies for cancer, with Telix receiving an upfront payment of $40 million. The partnership includes a 50/50 cost and profit-sharing model for global commercialization, with potential milestones for Telix reaching up to $2.1 billion. This collaboration leverages Telix's radiopharmaceutical expertise and Regeneron's antibody technologies to advance precision oncology treatments and radio-diagnostics.

Arqit Quantum (ARQQ) reported preliminary unaudited revenue of $620,000–$630,000 for the first half of fiscal 2026, a substantial increase from $67,000 in the prior-year period and exceeding its full-year 2025 revenue of $530,000. This growth was attributed to existing contracts and three new agreements. Despite positive revenue momentum, TipRanks' AI Analyst, Spark, rates ARQQ as Neutral due to weak financial performance and bearish technicals, even though one analyst maintains a Buy rating with a $60.00 price target.

Merck & Co., Inc. faces a critical juncture regarding the sustained growth of its stock, which is heavily reliant on its blockbuster cancer drug, Keytruda, and the looming patent expiration around 2028. The article emphasizes the importance of Merck's pipeline diversification and R&D execution for its future performance in the U.S. market, especially given the volatility in the healthcare sector and increasing competitive pressures. While analysts are generally positive, citing Keytruda's demand and new drug launches, investors are advised to monitor regulation, patent cliffs, and pipeline developments closely.

Running Oak Capital LLC decreased its holdings in Jacobs Solutions Inc. by 10.2% in the fourth quarter, selling 11,901 shares and retaining 104,373 shares valued at approximately $13.8 million. Jacobs Solutions has a "Moderate Buy" consensus rating from analysts with an average price target of $156.60, and recently reported strong quarterly earnings and increased its dividend. Other institutional investors have also adjusted their stakes in the company, and an insider transaction saw President Shannon Miller sell a portion of her shares.

This article provides a comprehensive overview of the FundX ETF (XCOR), including its price, key statistics, and performance. It details the fund's investment strategy, which involves investing in ETFs synced with market leaders, primarily core equity funds globally. The article also covers frequently asked questions about ETFs, XCOR's specifics like AUM and expense ratio, and its technical analysis.

Running Oak Capital LLC decreased its stake in General Dynamics Corporation by 11.2% in Q4, now holding 47,217 shares valued at $15.90 million. Despite this, General Dynamics beat Q4 earnings and revenue estimates, raised its quarterly dividend, and received a "Moderate Buy" consensus rating from analysts with an average target price of $384.53. Insiders, including CEO Phebe Novakovic, have sold a total of 51,260 shares in the past three months.

Sippican Capital Advisors significantly reduced its stake in Citigroup Inc. by selling 13,578 shares, cutting its holdings by 48.8% to 14,237 shares valued at $1.661 million. This sale comes as institutional investors like Capital World Investors and Franklin Resources are increasing their positions, while Citigroup insider Cantu Ernesto Torres also sold a substantial number of shares. Analysts maintain a "Moderate Buy" rating for Citigroup with a consensus price target of $127.41, and the company is preparing to release its Q1 earnings on April 14th.

Running Oak Capital LLC reduced its stake in Roper Technologies by 22.3%, selling 6,712 shares and now holding 23,435 shares valued at $10.432 million. Despite this, Director Thomas Patrick Joyce Jr. recently bought 1,400 shares. Wall Street analysts maintain a "Hold" consensus with a target price of $476.60, and Roper Technologies provided a FY2026 EPS guidance of $21.300-$21.550.

Running Oak Capital LLC reduced its stake in STERIS plc (NYSE:STE) by 10.1%, selling 6,781 shares and now owning 60,038 shares valued at $15.22 million. Concurrently, STERIS director Cynthia L. Feldmann sold 3,098 shares, reducing her position by over 81%. Analysts maintain a "Moderate Buy" rating for STERIS with a target price of $275.20, following strong Q4 earnings, increased revenue, and positive FY2026 guidance.